Table 1.

Hazard ratios and incidence rates (per 1000 person-years) for first cardiovascular events according to magnitude of per cent reduction in cholesterol while on statin therapy in the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin trial

	N	Events	Rate (95% CI)	HR (95% CI)	HR (adjusted)a (95% CI)
LDLC
Placebo	7743	189	11.2 (9.7–12.9)	1.00	1.00
No reduction/increase	851	15	9.2 (5.6–15.3)	0.91 (0.54–1.53)	0.86 (0.50–1.49)
>0 but <50% reduction	3365	49	6.7 (5.1–8.9)	0.61 (0.44–0.83)	0.61 (0.44–0.83)
≥50% reduction	3640	40	4.8 (3.5–6.6)	0.42 (0.30–0.60)	0.41 (0.29–0.58)
P (all groups)				<0.000001	<0.000001
P (rosuvastatin allocated only)				0.010	0.022
Non-HDLC
Placebo	7847	190	11.1 (9.6–12.8)	1.00	1.00
No reduction/increase	838	16	10.0 (6.1–16.3)	0.99 (0.60–1.66)	1.04 (0.62–1.74)
>0 but <50% reduction	4887	64	6.0 (4.7–7.6)	0.54 (0.41–0.71)	0.53 (0.40–0.70)
≥50% reduction	2185	26	5.2 (3.6–7.7)	0.46 (0.31–0.70)	0.44 (0.29–0.67)
P (all groups)				<0.000001	<0.000001
P (rosuvastatin allocated only)				0.046	0.056
Apolipoprotein B
Placebo	7786	188	11.0 (9.6–12.8)	1.00	1.00
No reduction/increase	580	14	11.9 (7.0–20.1)	1.14 (0.66–1.97)	1.15 (0.67–2.00)
<50% reduction	5807	74	5.7 (4.6–7.2)	0.51 (0.39–0.67)	0.50 (0.38–0.65)
≥50% reduction	1440	14	4.7 (2.8–7.9)	0.43 (0.25–0.75)	0.41 (0.24–0.71)
P (all groups)				<0.000001	<0.000001
P (rosuvastatin allocated only)				0.024	0.041

^aAdjusted estimates control for baseline lipid levels, gender, ethnicity, smoking status, hypertension, family history of coronary heart disease, body mass index, and age.